AMENDMENTS TO THE CLAIMS:

The following listing of claims replaces all prior listings, and all prior versions, of claims in the application.

Listing of Claims:

1. (Currently Amended) A pharmaceutical preparation comprising a compound (I)

~~(i)~~ which ~~can be~~ is obtained by reacting a compound (II) having a free amino group~~, said compound (II) having a free amino group being~~ selected from the group B ~~consisting of doxorubicin, peptides, proteins, enzymes and dopamine~~, with a sugar (III) having the reducing power and selected from the group A, wherein an amino group of said compound (II) ~~having a free amino group~~ reacts with an aldehyde group in said sugar (III)~~; having the reducing power, , and~~

~~(ii) which~~ wherein said compound (I) can rapidly ~~releases~~ release said compound (II) having a free amino group in response to changes in pH,

wherein the group B consists of doxorubicin and a peptide, and the group A consists of ~~glucose,~~ lactose, ~~fucosylglucose, galactosyllactose, fucosyllactose, lacto-N-tetraose, lacto-N-hexaose, lacto-N-neohexaose, dimannosyl-N-acetylglucosamine,~~ sialyllactose~~, disialyllactose, N,o-diacetylneuraminyllactose, 3'-sialyllactose 6'-sulfate, lactose 6'-sulfate, lactose 3'-phosphate, disialylacto-N-tetraose, glycolipids,~~ and compounds prepared by chemically binding a polymer selected from the group consisting of polyoxyethylene, polyglutamic acid and polyvinylpyrrolidone to a hydroxyl group other than the hydroxyl group formed from the reducing aldehyde

group of a sugar selected from the group ~~B~~C, wherein the group ~~B~~ C consists of ~~glucose, lactose, fucosylglucose, galactosyllactose, fucosyllactose, lacto-N-tetraose, lacto-N-hexaose, lacto-N-neohexaose, dimannosyl-N-acetylglucosamine,~~ and sialyllactose~~, disialyllactose, N,o-diacetylneuraminyllactose, 3'-sialyllactose 6'-sulfate, lactose 6'-sulfate, lactose 3'-phosphate, disialyllacto-N-tetraose, and glycolipids~~.

2. (Currently Amended) The preparation according to claim 1, wherein said compound (II) ~~having a free amino group selected from the group consisting of doxorubicin, peptides, proteins, enzymes and dopamine~~ is a pharmaceutical compound.

3. (Currently Amended) The preparation according to claim 1, wherein said compound (II) is a peptide ~~having a free amino group is selected from the group consisting of peptides, proteins, enzymes and amino acid derivatives dopamine~~.

4. (Currently Amended) The preparation according to claim 1~~(1)~~, wherein said peptide is insulin.

5. (Currently Amended) The preparation according to claim 1, which is obtained by the following steps:

~~wherein at least one of~~ said compound (II) ~~having a free amino group selected from the group consisting of doxorubicin, peptides, proteins, enzymes and~~

~~dopamine,~~ is modified with a pharmaceutical carrier, and the modified compound (II) is reacted with said sugar (III) to give said compound (I);

said compound (II) and said sugar (III) ~~having the reducing power selected from group A, is modified with or~~ are encapsulated in a pharmaceutical carrier, and said compound (II) is reacted with said sugar (III) to give said compound (I) in the pharmaceutical carrier; or

~~said compound (I) which can be obtained by reacting~~ said compound (II) ~~having a free amino group~~ is reacted with said sugar (III) to give said compound (I) ~~having the reducing power selected from the group A, wherein an amino group of said compound (II) having a free amino group reacts with an aldehyde group in said sugar (III) having the reducing power~~, and said compound (I) is modified with or ~~included~~ encapsulated in ~~a~~ the pharmaceutical carrier.

6.-8. (Cancelled)

9. (Currently Amended) The preparation according to claim 2, which is obtained by the following steps:

~~wherein at least one of~~ said pharmaceutical compound~~, and said sugar (III) having the reducing power selected from group A~~, is modified with ~~or encapsulated in~~ a pharmaceutical carrier, and the modified pharmaceutical compound is reacted with said sugar (III) to give said compound (I);

said pharmaceutical compound and said sugar (III) are encapsulated in a pharmaceutical carrier, and said pharmaceutical compound is reacted with said

sugar (III) to give said compound (I) in said pharmaceutical carrier; or

~~a compound which can be obtained by reacting~~ said pharmaceutical compound is reacted with said sugar (III) to give said compound (I), ~~having the reducing power selected from group A, wherein an aldehyde group in said sugar (III) having the reducing power~~ and said compound (I) is modified with or encapsulated in ~~a~~ said pharmaceutical carrier.

10.-12. (Cancelled)

13. (Currently Amended) The preparation according to claim 3, which is obtained by the following steps:

~~wherein at least one of said compound having a free amino group selected from the group consisting of peptides, proteins, enzymes and dopamine,~~ said peptide is modified with a pharmaceutical carrier, and the modified peptide is reacted with said sugar (III) to give said compound (I);

said peptide and said sugar (III) ~~having the reducing power selected from the group A, is modified with~~ are encapsulated in a pharmaceutical carrier, and said peptide is reacted with said sugar (III) to give the compound (I) in the pharmaceutical carrier; or

~~a compound which can be obtained by reacting said compound having a free amino group~~ said peptide is reacted with said sugar (III) ~~having the reducing power selected from group A~~ to give said compound (I), ~~wherein an amino group of said compound having a free amino group reacts with an aldehyde group in said sugar~~

~~(III) having the reducing power~~ and said compound (I) is modified with or encapsulated in the pharmaceutical carrier.

14.-16. (Cancelled)

17. (Currently Amended) The preparation according to Claim 4, which is obtained by the following steps:

~~wherein at least one of~~ insulin~~, and said sugar (III) having the reducing power selected from the group A,~~ is modified with ~~or encapsulated in~~ a pharmaceutical carrier, and the modified insulin is reacted with said sugar (III) to give said compound (I);

insulin and said sugar (III) are encapsulated in a pharmaceutical carrier, and said insulin is reacted with said sugar (III) to give said compound (I); or

~~a compound which can be obtained by reacting~~ insulin is reacted with said sugar (III) ~~having the reducing power selected from group A~~ to give said compound (I), ~~wherein an amino group of said insulin reacts with an aldehyde group in said sugar (III) having the reducing power~~ and said compound (I) is modified with or encapsulated in the pharmaceutical carrier.

18.-20. (Cancelled)

21. (Currently Amended) The preparation according to claim 1, wherein said compound (II) ~~having a free amino group selected from the group consisting of~~

~~doxorubicin, peptides, proteins, enzymes and dopamine~~ is enkephalin ~~a peptide~~.

22. (Cancelled)

23. (Currently Amended) The preparation according to claim 21, which is obtained by the following steps:

~~wherein at least one of said peptide, and said sugar (III) having the reducing power selected from the group A,~~enkephalin is modified with ~~or encapsulated in~~ a pharmaceutical carrier and the modified enkephalin is reacted with said sugar (III) to give said compound (I);

enkephalin and said sugar (III) are encapsulated in a pharmaceutical carrier, and said enkephalin is reacted with said sugar (III) to give said compound (I) in the pharmaceutical carrier; or

~~a compound which can be obtained by reacting said peptide~~ enkephalin is reacted with said sugar (III) ~~having the reducing power selected from group A~~to give said compound (I), ~~wherein an amino group of said peptide reacts with an aldehyde group in said sugar (III) having the reducing power~~ and said compound (I) is modified with or encapsulated in the pharmaceutical carrier.

24.-60. (Cancelled)

61. (New) The preparation according to claim 1, which is obtained by the following steps:

said compound (II) and said sugar (III) are encapsulated in a pharmaceutical carrier, and said compound (II) is reacted with said sugar (III) to give said compound (I) in the pharmaceutical carrier.

62. (New) The preparation according to claim 5 or 61, wherein said pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.

63. (New) The preparation according to claim 2, which is obtained by the following steps:

said pharmaceutical compound and said sugar (III) are encapsulated in a pharmaceutical carrier, and said pharmaceutical compound is reacted with said sugar (III) to give said compound (I) in the pharmaceutical carrier.

64. (New) The preparation according to claim 9 or 63, wherein said pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.

65. (New) The preparation according to claim 3, which is obtained by the following steps:

said peptide and said sugar (III) are encapsulated in a pharmaceutical carrier,

and said peptide is reacted with said sugar (III) to give said compound (I) in the pharmaceutical carrier.

66. (New) The preparation according to claim 13 or 65, wherein said pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.

67. (New) The preparation according to claim 4, which is obtained by the following steps:

insulin and said sugar (III) are encapsulated in a pharmaceutical carrier, and said insulin is reacted with said sugar (III) to give said compound (I) in the pharmaceutical carrier.

68. (New) The preparation according to claim 17 or 67, wherein said pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.

69. (New) The preparation according to claim 21, which is obtained by the following steps:

enkephalin and said sugar (III) are encapsulated in a pharmaceutical carrier, and said enkephalin is reacted with said sugar (III) to give said compound (I) in the

pharmaceutical carrier.

70. (New) The preparation according to claim 23 or 69, wherein said pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.

71. (New) The preparation according to claim 1, which is obtained by the following steps:

said compound (II) is modified with a pharmaceutical carrier, and the modified compound (II) is reacted with said sugar (III) to give said compound (I);

or

said compound (II) is reacted with said sugar (III) to give said compound (I), and said compound (I) is modified with the pharmaceutical carrier.

72. (New) The preparation according to claim 71, wherein said pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.

73. (New) The preparation according to claim 2, which is obtained by the following steps:

said pharmaceutical compound is modified with a pharmaceutical carrier, and

the modified pharmaceutical compound is reacted with said sugar (III) to give said compound (I);

or

said pharmaceutical compound is reacted with said sugar (III) to give said compound (I), and said compound (I) is modified with said pharmaceutical carrier.

74. (New) The preparation according to claim 73, wherein said pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.

75. (New) The preparation according to claim 3, which is obtained by the following steps:

said peptide is modified with a pharmaceutical carrier, and said modified peptide is reacted with said sugar (III) to give the compound (I);

or

said peptide is reacted with said sugar (III) to give said compound (I), and said compound (I) is modified with the pharmaceutical carrier.

76. (New) The preparation according to claim 75, wherein said pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.

77. (New) The preparation according to claim 4, which is obtained by the following steps:

insulin is modified with a pharmaceutical carrier, and the modified insulin is reacted with said sugar (III) to give said compound (I);

or

insulin is reacted with said sugar (III) to give said compound (I), and said compound (I) is modified with the pharmaceutical carrier.

78. (New) The preparation according to claim 77, wherein said pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.

79. (New) The preparation according to claim 21, which is obtained by the following steps:

enkephalin is modified with a pharmaceutical carrier, and said modified enkephalin is reacted with said sugar (III) to give said compound (I);

or

enkephalin is reacted with said sugar (III) to give said compound (I), and said compound (I) is modified with the pharmaceutical carrier.

80. (New) The preparation according to claim 79, wherein said

pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.